Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia

This publication has 21 references indexed in Scilit:

• Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy
  Pediatric Blood & Cancer, 2010
• Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation
  Hematology-American Society Hematology Education Program, 2010
• Imatinib mesylate in children and adolescents with cancer
  Pediatric Blood & Cancer, 2010
• Imatinib mesylate causes growth plate closure in vivo
  Leukemia, 2009
• Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib
  Haematologica, 2009
• Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT
  Bone Marrow Transplantation, 2008
• Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms
  Journal of Bone and Mineral Research, 2007
• Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
  Leukemia, 2005
• Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
  Blood, 2004
• The Infancy‐Childhood‐Puberty Model of Growth: Clinical Aspects
  Acta Paediatrica, 1989